Together we improve patient care and fight AMR through cutting edge molecular microbiology.
OpGen, along with its subsidiaries, Curetis and Ares Genetics, develop and commercialize molecular microbiology solutions to help guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes.
OpGen’s product portfolio includes the Unyvero System and multiplex syndromic panels, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb using next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for antibiotic response prediction.